Tuncay Duruöz, Bhowmik Meghnathi, Carla G S Saad, Feng Huang, Denis Poddubnyy, Alberto Cauli, Alexandre Sepriano, Sibel Zehra Aydin, Jo Davies, Simeon Grazio, Floris van Gaalen, Rodrigo Garcia-Salinas, Marco Garrido Cumbrera, Lianne Gensler, Ying Ying Leung, Helena Marzo-Ortega, Martin Rudwaleit, James Wei, Maxime Dougados, Murat Torgutalp, Mitsumasa Kishimoto, Bassel El-Zorkany, Robert Landewé, Pál Géher, Anna Molto, Suzanne Arends, Warren Fong, Sofia Ramiro, Désirée van der Heijde, Xenofon Baraliakos, Filip van den Bosch, Pedro M Machado, Victoria Navarro-Compán, Simone Battista, Elena Nikiphorou, Christine Bundy
Journal: Annals of the rheumatic diseases 2025;84(4):538-546
PMID: 39955166
OBJECTIVES
To develop a consensus-based expert definition of difficult-to-manage (D2M) axial spondyloarthritis (axSpA), incorporating treatment-refractory (TR) disease.
METHODS
A literature review was conducted in 2022 to identify potential definitions for D2M/TR axSpA from prior studies, followed by a 2-round Delphi consensus process conducted in 2022 and 2023 to identify components of D2M axSpA. Based on the results of the Delphi process, a draft of the D2M axSpA definition was developed and presented to the expert task force, including patient representation, and, subsequently, to the Assessment of SpondyloArthritis International Society (ASAS) membership for endorsement in January 2024.
RESULTS
Consensus was reached on a D2M definition encapsulating treatment failure (treatment according to the ASAS-European Alliance of Associations for Rheumatology recommendations and failure of ≥2 biological or targeted synthetic disease-modifying antirheumatic drugs with different mechanisms of action unless contraindicated), suboptimal disease control, and physician or patient acknowledgement of problematic signs/symptoms in patients diagnosed with axSpA by the rheumatologist. This definition represents a broad concept that includes various reasons that lead to an unsatisfactory treatment outcome. TR axSpA is covered by the D2M definition but requires a history of treatment failure, the presence of objective signs of inflammatory activity, and the exclusion of noninflammatory reasons for nonresponse. The proposed D2M definition incorporating TR disease was endorsed by ASAS at the annual meeting in January 2024, with 89% votes (109/123) in favour of it.
CONCLUSIONS
The ASAS D2M axSpA definition, including TR disease, allows for identifying patients with unmet needs, paving the way for further research in this condition and its clinical care improvement.
Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.